Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer
Pfizer's oral selective VEGF inhibitor axitinib in combination with standard chemotherapy improves overall survival by 1.3 months and decreased the risk of death by 33 percent compared to standard care in advanced pancreatic cancer patients, the firm reported during a June 4 presentation at the American Society of Clinical Oncology meeting in Chicago
You may also be interested in...
Pfizer is seeking to maximize the value of its oncology pipeline by developing combination regimens, Senior VP-Worldwide Development Declan Doogan said Nov. 30
Genentech and marketing partner OSI are highlighting the overall survival benefit of combination use with Tarceva over gemcitabine (Lilly's Gemzar) plus placebo for treatment of advanced pancreatic cancer
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.